Clinical Trial Update: Adjuvant PEG Intron in Ulcerated Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial update for adjuvant PEG Intron in ulcerated melanomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma
• Ulcerated Melanoma

Drugs mentioned

• PEG Intron (pegylated interferon alfa-2b)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Ulcerated Melanomas | Phase 3 | Status: UNKNOWN